Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.08 -6.6%	$0.23	$0.07 ▼ $1.33	$20.54M	2.18	50.01 million shs	26.02 million shs
KTTA Pasithea Therapeutics	$0.68 -2.6%	$0.75	$0.65 ▼ $7.50	$5.08M	0.26	119,560 shs	92,343 shs
MBRX Moleculin Biotech	$0.67 -0.4%	$0.59	$0.25 ▼ $3.65	$20.38M	1.39	3.95 million shs	414,077 shs
RLMD Relmada Therapeutics	$0.59 -2.4%	$0.65	$0.24 ▼ $3.98	$19.50M	0.66	195,011 shs	80,531 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	-3.00%	-71.75%	-73.51%	-92.33%
KTTA Pasithea Therapeutics	0.00%	-2.32%	-1.27%	-18.45%	-85.64%
MBRX Moleculin Biotech	0.00%	+1.41%	+26.31%	-35.76%	-69.34%
RLMD Relmada Therapeutics	0.00%	-0.51%	-12.34%	+39.89%	-81.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.769 of 5 stars	4.0	4.0	0.0	2.3	0.8	0.0
KTTA Pasithea Therapeutics	0.7469 of 5 stars	0.0	5.0	0.0	0.6	0.8	0.6
MBRX Moleculin Biotech	2.6027 of 5 stars	3.5	2.0	0.0	1.9	1.7	1.3
RLMD Relmada Therapeutics	4.6396 of 5 stars	3.1	5.0	4.4	1.7	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,644.09% Upside
KTTA Pasithea Therapeutics	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$4.00	493.03% Upside
RLMD Relmada Therapeutics	2.25	Hold	$5.00	751.21% Upside

Current Analyst Ratings Breakdown

Latest KTTA, ADAP, MBRX, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.12	N/A	N/A	$0.05 per share	1.55
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$10.60 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
KTTA Pasithea Therapeutics	-$13.90M	-$10.60	N/A	∞	N/A	N/A	-88.14%	-81.21%	8/12/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/12/2025 (Estimated)
RLMD Relmada Therapeutics	-$79.98M	-$2.22	N/A	N/A	N/A	N/A	-223.17%	-180.41%	N/A

Latest KTTA, ADAP, MBRX, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.42	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
8/7/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A
5/15/2025	Q1 2025	KTTA Pasithea Therapeutics	N/A	-$1.61	N/A	-$1.61	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/12/2025	Q1 2025	RLMD Relmada Therapeutics	-$0.31	-$0.58	-$0.27	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
KTTA Pasithea Therapeutics	N/A	3.84	3.84
MBRX Moleculin Biotech	N/A	1.35	1.35
RLMD Relmada Therapeutics	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
KTTA Pasithea Therapeutics	23.92%
MBRX Moleculin Biotech	15.52%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
KTTA Pasithea Therapeutics	2.70%
MBRX Moleculin Biotech	2.10%
RLMD Relmada Therapeutics	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
KTTA Pasithea Therapeutics	3	7.44 million	7.24 million	Not Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable

KTTA, ADAP, MBRX, and RLMD Headlines

Recent News About These Companies

Relmada Therapeutics (NASDAQ:RLMD) Upgraded to Hold at Wall Street Zen

August 9 at 3:37 AM | americanbankingnews.com

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

August 8 at 2:10 PM | seekingalpha.com

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 31, 2025 | globenewswire.com

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15, 2025 | finance.yahoo.com

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15, 2025 | globenewswire.com

Relmada terminates license agreement for troubled phase 3 depression asset

July 11, 2025 | fiercebiotech.comF

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

July 9, 2025 | globenewswire.com

Relmada Therapeutics Inc News (RLMD) - Investing.com

July 2, 2025 | investing.com

RLMD Relmada Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Relmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With Losses

June 28, 2025 | uk.finance.yahoo.com

Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RLMD - Relmada Therapeutics Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Relmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder Cancer

June 17, 2025 | quiverquant.comQ

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

June 17, 2025 | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in Stock

May 21, 2025 | insidertrades.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025 | globenewswire.com

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer

April 28, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, ADAP, MBRX, and RLMD Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.08 -0.01 (-6.63%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.08 +0.00 (+2.97%)

As of 08/8/2025 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Pasithea Therapeutics NASDAQ:KTTA

$0.68 -0.02 (-2.57%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.68 -0.01 (-1.03%)

As of 08/8/2025 07:58 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Moleculin Biotech NASDAQ:MBRX

$0.67 0.00 (-0.43%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.62 -0.06 (-8.23%)

As of 08/8/2025 07:59 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Relmada Therapeutics NASDAQ:RLMD

$0.59 -0.01 (-2.41%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.62 +0.03 (+4.70%)

As of 08/8/2025 07:59 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time